Study: NCT02538393

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib (BAY43-9006) Film-coated tablet
Description: Subjects received a single oral dose of 400 mg sorafenib marketed tablets (2 \* 200 mg) in fasting state in Treatment A

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib (BAY43-9006) Film-coated tablet
Description: Subjects received a single oral dose of 400 mg sorafenib marketed tablets (2 \* 200 mg) in fasting state in Treatment A

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib (BAY43-9006) Film-coated tablet
Description: Subjects received a single oral dose of 400 mg sorafenib marketed tablets (2 \* 200 mg) in fasting state in Treatment A

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib (BAY43-9006) Film-coated tablet
Description: Subjects received a single oral dose of 400 mg sorafenib marketed tablets (2 \* 200 mg) in fasting state in Treatment A

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib (BAY43-9006) Oral suspension
Description: Treatment C: Subjects received a single oral dose of 200 mg sorafenib tablets for oral suspension (2 \* 100 mg) in fasting state in the second intervention period; Treatment B: Subjects received a single oral dose of 400 mg sorafenib tablets for oral suspension (4 \* 100 mg) in fasting state in the third intervention period; Treatment D: Subjects received a single oral dose of 400 mg sorafenib tablets for oral suspension (4 \* 100 mg) after a high-fat, high-calorie breakfast (fed state) in the fourth intervention period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib (BAY43-9006) Oral suspension
Description: Treatment C: Subjects received a single oral dose of 200 mg sorafenib tablets for oral suspension (2 \* 100 mg) in fasting state in the second intervention period; Treatment B: Subjects received a single oral dose of 400 mg sorafenib tablets for oral suspension (4 \* 100 mg) in fasting state in the third intervention period; Treatment D: Subjects received a single oral dose of 400 mg sorafenib tablets for oral suspension (4 \* 100 mg) after a high-fat, high-calorie breakfast (fed state) in the fourth intervention period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib (BAY43-9006) Oral suspension
Description: Treatment C: Subjects received a single oral dose of 200 mg sorafenib tablets for oral suspension (2 \* 100 mg) in fasting state in the second intervention period; Treatment B: Subjects received a single oral dose of 400 mg sorafenib tablets for oral suspension (4 \* 100 mg) in fasting state in the third intervention period; Treatment D: Subjects received a single oral dose of 400 mg sorafenib tablets for oral suspension (4 \* 100 mg) after a high-fat, high-calorie breakfast (fed state) in the fourth intervention period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib (BAY43-9006) Oral suspension
Description: Treatment C: Subjects received a single oral dose of 200 mg sorafenib tablets for oral suspension (2 \* 100 mg) in fasting state in the second intervention period; Treatment B: Subjects received a single oral dose of 400 mg sorafenib tablets for oral suspension (4 \* 100 mg) in fasting state in the third intervention period; Treatment D: Subjects received a single oral dose of 400 mg sorafenib tablets for oral suspension (4 \* 100 mg) after a high-fat, high-calorie breakfast (fed state) in the fourth intervention period.